Acrs stock forecast shows recent bullish momentum, with the share price hovering near $8.20 after a 12% weekly gain. Analysts point to strong biotech sector demand and upcoming Phase 3 trial data as short-term catalysts, while broader Nasdaq biotech index movements could influence volatility. While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. There are plenty of analysts covering the stock, so it might be worth seeing what they are forecasting, too. Aclaris Therapeutics (ACRS) is expected to deliver a year-over-year increase in earnings on lower revenues when it reports results for the quarter ended June 2025. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price. Current acrs stock forecast incorporates RSI readings showing neutral territory at 54, indicating room for upward movement. With institutional holdings increasing by 3%, accumulation trends support a medium-term bullish outlook.
